Getting Support

The CareZ Community:
Helping patients with Alpha-1–associated emphysema gain access to Zemaira and to physical, financial, and emotional support*

People who are prescribed Zemaira are able to take advantage of the CareZ program, a comprehensive suite of services that helps make the management of Alpha-1 as easy as possible. CareZ provides a number of resources that help patients get the treatment and support they need, including:

  • Zemaira product samples – Patients with Alpha-1–associated emphysema are given the option of trying Zemaira for up to 2 weeks
  • My Steps for Healthy Living program – Challenges you to live healthy by adopting a regular walking program
  • Insurance and reimbursement support – Provides expert assistance in dealing with issues related to health insurance coverage
  • Patient Support Specialists – Alphas like you who have been trained to help other patients manage the day-to-day difficulties of living with Alpha-1

* Emotional support does not constitute professional guidance or psychological or therapeutic counseling; our specialists offer experience-based, nontherapeutic advice and support in handling the difficulties of living with Alpha-1.

Important Safety Information

Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira are not available.

Zemaira may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.

In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).

Zemaira is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Do you want to continue?

No Yes